|
Video: What is a Stock Split?
|
|
Collegium Pharmaceutical is a pharmaceutical company. Co.'s portfolio includes: Xtampza ER, Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol. Xtampza ER was approved by the U.S. Food and Drug Administration for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. Nucynta ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic. According to our COLL split history records, Collegium Pharmaceutical has had 0 splits. | |
|
Collegium Pharmaceutical (COLL) has 0 splits in our COLL split history database.
Looking at the COLL split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Collegium Pharmaceutical shares, starting with a $10,000 purchase of COLL, presented on a split-history-adjusted basis factoring in the complete COLL split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
05/08/2015 |
|
End date: |
03/28/2024 |
|
Start price/share: |
$12.95 |
|
End price/share: |
$38.82 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
199.77% |
|
Average Annual Total Return: |
13.13% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$29,965.54 |
|
Years: |
8.90 |
|
|
|
|
|